Clinical trials: BK Virus Infection
BK Virus Infection, BKV Infection
A Trial to Evaluate the Safety, Tolerability and Efficacy of AIC263029 in Kidney Transplant Recipients With BKV Infection
The goal of this clinical trial is to learn if AIC263029 is safe and well tolerated in adult kidney transplant recipients with BK virus (BKV) in the blood (viremia).
- Conditions
- BK Virus Infection, BKV Infection, Kidney Transplant
- Trial name
- NCT07503561
- Testing
- AIC263029
- Where
- 7 sites in United States
- Volunteers
- 24 people
- Sponsor
- AiCuris Anti-infective Cures AG
EBV Viremia, CMV Viremia
25BT056: Basket Study of Viral Cytotoxic T Lymphocytes
This study is evaluating the safety and effectiveness of virus-specific cytotoxic T lymphocytes (vCTLs) for treating difficult-to-control viral infections caused by cytomegalovirus (CMV), adenovirus (ADV), Epstein-Barr virus…
- Conditions
- EBV Viremia, CMV Viremia, BK Viremia, Adenovirus
- Trial name
- NCT07873970
- Testing
- Virus-Specific Cytotoxic T Lymphocytes (vCTLs)
- Volunteers
- 35 people
- Sponsor
- Children's Hospital of Philadelphia
Kidney Diseases, Kidney Injury
ID-ENTITY Trial- Evaluating Serial T-ID Monitoring
To evaluate the association between time-updated CMV and BK viral loads measured monthly by T-ID and the risk of CMV disease and/or biopsy-proven BK virus-associated nephropathy (BKVAN) during the first 12 months following kidney…
- Conditions
- Kidney Diseases, Kidney Injury, BK Virus Infection, CMV
- Trial name
- ID-ENTITY (NCT07393594)
- Testing
- Blood tests, TRAC( cell free DNA) and T-ID
- Where
- 14 sites in United States
- Volunteers
- 1,000 people
- Sponsor
- Transplant Genomics, Inc.
Epstein-Barr Virus Infection, Cytomegalovirus Infections
TETRAVI Expanded Access Program
This Expanded Access Program (EAP) allows qualified physicians within Texas to obtain access to multivirus-specific cytotoxic T lymphocytes (VSTs) developed under Baylor College of Medicine's TETRAVI program (NCT04013802) for the…
- Conditions
- Epstein-Barr Virus Infection, Cytomegalovirus Infections, Adenovirus Infection, BK Virus Infection
- Trial name
- NCT07104591
- Testing
- HLA-matched VSTs (Multivirus-specific Cytotoxic T Lymphocytes)
- Sponsor
- Baylor College of Medicine
Acquired Immunodeficiency Syndrome, BK Virus Infection
Cytotoxic T Lymphocytes in Treating Patients With Malignancies With BK and/or JC Virus
This phase II trial studies how well donor cytotoxic T lymphocytes work in treating patients with malignancies with BK and/or JC virus.
- Conditions
- Acquired Immunodeficiency Syndrome, BK Virus Infection, Human Immunodeficiency Virus, JC Virus Infection
- Trial name
- NCT02479698
- Testing
- Allogeneic BK-specific Cytotoxic T-lymphocytes, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- M.D. Anderson Cancer Center
BK Virus Infection, Kidney Transplant; Complications
Immune Registry for BK in Kidney Transplant Recipients
Kidney transplantation (KT) is the best treatment modality available to date for patients with advanced kidney disease and the success of KT is dependent on maintaining a selective intricate balance between the risk of rejection…
- Trial name
- NCT06538961
- Testing
- Blood samples: Main Study group, Data Collection, Urine Sample- Main Study group
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Virginia Commonwealth University
Adenovirus Infection, BK Virus Infection
Study Assessing the Feasibility, Safety and Efficacy of Genetically Engineered Glucocorticoid Receptor Knock Out Virus Specific CTL Lines for Viral Infections in Immunosuppressed Cancer Patients
This phase I trial tests the feasibility and safety of genetically modified cytotoxic T-lymphocytes in controlling infections caused by adenovirus (ADV), BK virus (BKV), cytomegalovirus (CMV), JC virus (JCV), or COVID-19 in…
- Conditions
- Adenovirus Infection, BK Virus Infection, Cytomegaloviral Infection, Hematopoietic and Lymphoid Cell Neoplasm
- Trial name
- NCT05101213
- Testing
- Virus-specific Cytotoxic T-lymphocytes
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- M.D. Anderson Cancer Center
Epstein-Barr Virus, Cytomegalovirus Infections
R-MVST Cells for Treatment of Viral Infections in Children and Young Adults
The primary objective is to determine the safety and feasibility of administering R-MVST cells to patients with refractory viral reactivation and/or symptomatic disease caused by Epstein Barr Virus (EBV), cytomegalovirus (CMV)…
- Conditions
- Epstein-Barr Virus, Cytomegalovirus Infections, Adenovirus, BK Virus Infection
- Trial name
- NCT06926894
- Testing
- Rapidly generated virus specific T (R-MVST) cells
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Monica Bhatia
Epstein-Barr Virus Infections, Cytomegalovirus Infections
R-MVST Cells for Treatment of Viral Infections
The primary objective is to determine the safety and feasibility of administering R-MVST cells to patients with refractory viral reactivation and/or symptomatic disease caused by Epstein Barr Virus (EBV), cytomegalovirus (CMV)…
- Conditions
- Epstein-Barr Virus Infections, Cytomegalovirus Infections, Adenovirus, BK Virus Infection
- Trial name
- NCT05183490
- Testing
- Rapidly generated virus specific T (R-MVST) cells
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Columbia University
BK Viremia, Kidney Transplant Infection
A Trial to Treat Polyomavirus Infections (BKPyV) in Kidney and Simultaneous Kidney Pancreas Transplant Recipients
BEAT-BK will see the effect of immunosuppression reduction/modification with and without IVIG on BKPyV infection, allograft function, allograft loss, acute transplant rejection, immunosuppression load and death in kidney and…
- Conditions
- BK Viremia, Kidney Transplant Infection, Kidney Transplant Failure and Rejection
- Trial name
- BEAT-BK (NCT05325008)
- Testing
- Immunosuppression reduction/modification + intravenous immunoglobulin, Immunosuppression reduction/modification
- Where
- 13 sites in Australia
- Volunteers
- 280 people
- Sponsor
- The University of Queensland
Kidney Transplant Infection, BK Virus Infection
The Efficacy of Everolimus With Reduced-dose Tacrolimus Versus Reduced-dose Tacrolimus and Leflunomide in Treatment of BK Virus Infection in Kidney Transplantation Recipient
BK virus infection is one of the causes of renal allograft loss in the current era. Reduction of immunsuppression is the only intervention that prooved to be effective in treating of BK virus in kidney transplant recipient.
- Trial name
- ELF (NCT04542733)
- Testing
- Everolimus, reduced dose tacrolimus and Leflunomide
- Where
- Thailand
- Volunteers
- 50 people
- Sponsor
- King Chulalongkorn Memorial Hospital
Nephropathy, Opportunistic Viral Infection
Study of the Serotype and Genotype of BK Virus in Kidney Transplant Recipients and Their Donors to Identify Individuals at Risk of Nephropathy
The aim of this observational study is to characterize the urinary replication of BK polyomavirus (BKV) in kidney transplant recipients.
- Conditions
- Nephropathy, Opportunistic Viral Infection, Polyoma Virus Nephropathy, BK Nephropathy
- Trial name
- TYPIK (NCT07347769)
- Where
- France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Grenoble
Kidney Transplant Infection, BK Virus Infection
Prediction of BK Virus Reactivation in Kidney Transplant Recipient
There has been no effective predicting tool to accurately predict BKV reactivation after kidney transplantation. The aim is to elucidate the use of flow cytometric analysis for both intracellular cytokines and surface activation…
- Conditions
- Kidney Transplant Infection, BK Virus Infection, BK Virus Nephropathy
- Trial name
- NCT06219616
- Testing
- BKV immune monitoring
- Where
- Thailand
- Volunteers
- 80 people
- Sponsor
- King Chulalongkorn Memorial Hospital
BK Virus Infection
New Therapeutic Approach Against BK Virus Infection Based on Monoclonal Antibodies
BK virus (BKV) infection has a major negative impact on transplant recipients. No BKV-specific antiviral therapy is available, so there is an urgent need to develop new anti-BKV preventive and therapeutic strategies.
- Trial name
- AcMBK (NCT05264259)
- Where
- France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Strasbourg, France
Kidney Transplant Infection, BK Virus Infection
BK With VST for Kidney Transplant Patients
This study measures the safety, feasibility, and efficacy of viral-specific T cells (VST) against BK Virus (BKV) in adult kidney transplant recipients. Participants are expected to be on study for 52 weeks.
- Trial name
- NCT05042076
- Testing
- BK-specific T cells from Donor Lymphocytes
- Where
- United States
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- University of Wisconsin, Madison
BK Virus Infection, Nephropathy
Study to Confirm of the Safety and Tolerability of Brincidofovir in Subjects With BK Virus Infection (Viremia) After Kidney Transplantation
This is a Phase II, multicenter, open-label, randomized, standard of care (SOC) controlled, multiple ascending dose study to assess the safety and tolerability of IV Brincidofovir (BCV) in subjects with BKV infection after kidney…
- Conditions
- BK Virus Infection, Nephropathy, Kidney Transplantation
- Trial name
- NCT05511779
- Testing
- Brincidofovir
- Where
- Japan
- Volunteers
- 1 people
- Sponsor
- SymBio Pharmaceuticals
BK Virus Infection
Prospective Study of BK Virus Disease After Allogeneic Hematopoietic-cell Transplantation: Defining BK Disease's Natural History, Clinical Spectrum, Immunology, and Outcomes
This research study is evaluating the reactivation of BK virus in patients who have undergone allogeneic hematopoietic-cell transplantation.
- Trial name
- NCT03532971
- Testing
- Symptom index questionnaire, BK polyomavirus PCR, quality of life questionnaires
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Dana-Farber Cancer Institute
BK Virus Nephropathy, BK Virus Infection
Study of Posoleucel (Formerly Known as ALVR105; Viralym-M) in Kidney Transplant Patients With BK Viremia
The purpose of this study is to compare Posoleucel (formerly known as ALVR105; Viralym-M) to placebo in kidney transplant recipients who have high or low levels of BK virus in their blood.
- Trial name
- NCT04605484
- Testing
- Posoleucel (formerly known as ALVR105) cells
- Where
- 33 sites in United States
- Volunteers
- 61 people
- Sponsor
- AlloVir
Adenovirus Infection, BK Virus Infection
Study of Posoleucel (ALVR105,Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell Transplant
This is a Phase 3 study to evaluate posoleucel (ALVR105, Viralym-M); an allogeneic, off-the-shelf multi-virus specific T cell therapy that targets six viral pathogens: BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus…
- Conditions
- Adenovirus Infection, BK Virus Infection, Cytomegalovirus Infections, Epstein-Barr Virus Infections
- Trial name
- Prevent (NCT05305040)
- Testing
- Posoleucel (ALVR105)
- Where
- 88 sites in United States, Australia and 8 more
- Volunteers
- 451 people
- Sponsor
- AlloVir
BK Virus Infection, Hemorrhagic Cystitis
Study to Evaluate Viralym-M (ALVR105) for the Treatment of Virus-Associated Hemorrhagic Cystitis (HC)
Study to Evaluate Viralym-M (ALVR105) for the Treatment of Virus-Associated Hemorrhagic Cystitis (HC).
- Trial name
- NCT04390113
- Testing
- Posoleucel (ALVR105)
- Where
- 56 sites in United States, France and 5 more
- Volunteers
- 97 people
- Sponsor
- AlloVir